

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.
In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail

(Translation)

April 20, 2022

To: Shareholders,

Company Name Renascience Inc.
Name of Representative: Koji Naito, President and CEO
(Code: 4889 TSE Growth)
Inquiries: Kazuhiro Ikeda, Director, CFO

**Notice of Adoption in AMED Program of "Innovation in Medical Engineering
(Development and Commercialization Project)" in FY2022**

The Company is pleased to announce that the project to develop an artificial intelligence (AI) to predict insulin dosage for diabetes patients is adopted in a program by the Japan Agency for Medical Research and Development (AMED) in FY2022.

Particulars

1. Adopted Projects

Name of Program: Innovation in Medical Engineering (Development and Commercialization Project) in FY2022

Name of Project: Development of Artificial Intelligence (AI) to Predict Insulin Dosage for Diabetic Patients

Representative of the Project: Koji Naito, President & CEO, Renascience Inc

2. Background

Insulin therapy is necessary to strictly control blood glucose levels in diabetic patients and to prevent diabetic complications. However, the safe dose range of insulin is narrow and the overdosing results in hypoglycemia, so the optimal type and dose must be selected carefully for each patient. However, since diabetes specialists account for less than 2% of all physicians and are geographically unevenly distributed, diabetes patients currently do not always see their primary care physician as a diabetes specialist, but rather often see a non-specialist physician.

3. Purpose of the Project

In this project, the Company will conduct clinical research aiming for regulatory approval of RSAI003 (support system for diabetes treatment that uses AI as its core technology to predict insulin dosage for diabetes patients) with a research grant from AMED.

This AI can predict insulin dosage for hospitalized diabetic patients with the same accuracy as diabetes specialists. It predicts the necessary insulin dosage from blood glucose levels measured by simple blood glucose monitoring, as well as patient information and basic blood biochemistry data. It can reduce the progression of chronic diabetic complications and adverse events during hospitalization (e.g. death, new onset of infection or respiratory failure, etc.). Non-specialists are taking time out of their own specialties (e.g. surgery, treatment of other diseases, etc.) to care for

diabetic inpatients, and this AI will reduce some of their working hours. For patients, this AI will lead to the suppression of the progression of chronic diabetic complications by improving blood glucose levels.

The term of this project supported by AMED is three years from the fiscal year ended March 31, 2023 to the fiscal year ended March 31, 2025.

The grant to be received in the fiscal year ended March 31, 2023 is approximately 52 million yen, and the accurate amount and the timing will be determined by AMED.

4. Outlook for the future

The impact on the full-year results for the fiscal year ended March 31, 2023 is currently being closely examined and will be incorporated into the full-year results forecast for the fiscal year ended March 31, 2023 in the financial results to be announced on May 12, 2022.

End